Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 15/20 | 0.58 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925502 | 0.85 | KCNH2 (0.57) | KCNH2 | |
| SCHEMBL2923635 | 0.83 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL4071573 | 0.79 | KCNH2 (0.63) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL4067873 | 0.77 | KCNH2 (0.63) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL2919418 | 0.77 | KCNH2 (0.55) | KCNH2 | |
| SCHEMBL3919654 | 0.75 | CCR8 (0.67) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL3919647 | 0.75 | CCR8 (0.67) | KCNH2KCNQ1CACNA1C | |
| Hydrochloric Acid SCHEMBL3923840 | 0.75 | CCR8 (0.66) | KCNH2KCNQ1CACNA1C | |
| Hydrochloric Acid SCHEMBL3923830 | 0.75 | CCR8 (0.66) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL3279129 | 0.74 | KCNH2 (0.72) | KCNH2KCNQ1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4654035-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | claimed |
| US-20070004710-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2007-01-04 | — | — | US | claimed |
| EP-1560488-A4 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1560488-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-10 | — | — | EP | claimed |
| WO-2004041210-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-21 | — | — | WO | claimed |
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-7618959-B2 | Antibacterial agents | SMITHKLINEBEECHAM CORP (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070004710-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004710-A1 | Antibacterial agents | NQO2, NRDC, IFNG | KCNH2 3365/4885KCNQ1 1816/4885CACNA1C 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.